Methylome Variation Predicts Exemestane Resistance in Advanced ER Breast Cancer

Methylome Variation Predicts Exemestane Resistance in Advanced ER Breast Cancer

Background: More than 30% of estrogen receptor-positive breast cancers are resistant to primary hormone therapy, and about 40% that initially respond to hormone therapy eventually acquire resistance. Although the mechanisms of hormone therapy resistance remain unclear, aberrant DNA methylation has b...

Full description

Bibliographic Details
Main Authors: Xiao-ran Liu PhD, Ru-yan Zhang MD, Hao Gong PhD, Hope S. Rugo MD, Ling-bo Chen PhD, Yuan Fu PhD, Jian-wei Che PhD, Jian Tie MD, Bin Shao MD, Feng-ling Wan, Wei-yao Kong MBBS, Guo-hong Song MD, Han-fang Jiang MD, Guo-bing Xu MD, Hui-ping Li MD
Format: Article
Language:English
Published: SAGE Publishing 2020-03-01
Series:Technology in Cancer Research & Treatment
Online Access:https://doi.org/10.1177/1533033819896331

Internet

https://doi.org/10.1177/1533033819896331

Similar Items